Skip to main content
FOLD logo

FOLD · AMICUS THERAPEUTICS, INC.

$14.49 +0.00 (+0.00%) At close · Apr 27
Market Cap
$4.55B
Shares
314.00M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.49 Open$14.49 Day$14.49–14.49 52W$5.51–14.50 Avg vol 30d3.0M Short int21.9M · 7.0% float · 7.5d Short vol73% Last earningsMay 4, 2026 DataJan 2020–Apr 2026 Filing10-K · Feb 20

Up next

Next earnings call
Aug 6, 2026 Est · unconfirmed · in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Feb 20, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 18.6 · elevated Equity put/call 0.79
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +33%
above
Price vs 50-day avg +1%
above
RSI (14) 70
overbought
MACD trend Negative
52-week position 100%
near high
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +60%
trailing
YTD return +2%
this year
Relative strength +56%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Distributing
32 of 297 funds reported for Jun 30 · net -3.2M sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.98% of float · ▲ +3.9% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
297 holders — mid 3-yr range
Fundamentals
Excellent
Revenue growth +20%
Y/Y
Gross margin 89%
contracting
EPS growth +50%
Y/Y
Free cash flow $29.8M
Balance sheet $178.7M
net debt
Quant / Vol
risk profile
Moderate
Volatility 46%
annualized · 1-yr
Max drawdown −27%
past year
ATR 0.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Sep 30, 2025
Combined sales · 2028 Initiated $1B
prior FY $634.21M midpoint +57.7% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
2 · 1 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+33% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
70 Bearish
MACD trend
Negative Bearish
52-week position
100% Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Distributing
32 of 297 funds reported for Jun 30 · net -3.2M sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.98% of float · ▲ +3.9% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
297 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $6 Now $14 · 100% 52-wk high $15
vs 200-day avg +33% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings
Metric Latest Period YoY
Non-GAAP net income non-GAAP $31.6M Q4 2025

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FOLD
AMICUS THERAPEUTICS, INC.
this stock
$4.55B +1.8% +20.0% 7.0%
ONC
BeOne Medicines Ltd.
$471.01B +7.6% +22179.2% 958.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$121.16B +4.4% +46.2% 28.3 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$68.78B -15.4% +20.8% 16.0 3.3%
ARGX
Argenx SE
$57.44B +9.9% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
266
% held
100.8%
Reported
32 of 297
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
137
View
Short & Settlement
Short Interest Rising
Shares short
21.9M
Days to cover
7.5d
Change
+824.6K sh
View
Short Volume
Short vol %
73%
As of
Apr 24, 2026
Short Total
View
Fails to Deliver
FTD shares
3.5K
Value
$50.6K
As of
Apr 28, 2026
View
Off-Exchange
Off-exchange %
47.5%
Week of
Apr 20, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$634.2M
Net income (FY)
$-27.1M
EPS diluted
$-0.09
View
Filings
SEC Filings
Latest
8-K
Filed
Apr 27, 2026
This year
6
View
Proposed Sales
Value
$323.3K
Shares
22.5K
Filed
Mar 2, 2026
View
Exempt Offerings
Offering
$30.0M
Filed
Oct 16, 2023
View
Earnings & Events
Earnings Calls
Last call
May 4, 2026
View

Performance

5D 20D 120D MTD YTD
FOLD +0.3% +0.6% +60.5% +0.2% +1.8%
SPY +1.0% +12.8% +4.9% +10.0% +4.9%
vs SPY -0.8% -12.2% +55.6% -9.8% -3.1%
Key facts CIK 1178879 CUSIP 03152W109 13F (30d) 1 filings 1 filers Visit website Investor relations